Menu
When PSA comes back elevated or an MRI shows a lesion, the next step does not have to be a blind biopsy or treatment of the entire prostate. A fusion biopsy finds the exact spot — and if the cancer is localized and you are a candidate, that area alone can be treated.
Image-guided diagnosis · Office-based, local anesthesiaFor years the prostate biopsy was taken by random sampling, and treating localized cancer meant operating on or irradiating the whole gland — even when the tumor occupied a small area. That exposes a man to risks of incontinence and erectile dysfunction that, in selected cases, can now be reduced.
Dr. Edward Gheiler, MD, FACS works with transperineal MRI/ultrasound fusion biopsy and with office-based focal ablation under local anesthesia. He is a co-author of published studies on both techniques, with reported follow-up at one and five years — references below.
Prostate cancer is one of the most common cancers in men. Risk rises with age and is higher with a family history or for men of African or Afro-Caribbean descent. Common does not mean aggressive: many cases are found localized and grow slowly.
Usually not. Early prostate cancer is typically silent, which is why it is found with PSA and examination rather than by how it feels. Urinary symptoms — weak stream, getting up at night, urgency — almost always come from an enlarged prostate (BPH), a separate and benign condition. When prostate cancer does cause symptoms (bone pain, blood in the urine or semen), it is usually more advanced. Waiting for symptoms is not a way to catch it early.
Follow-up is by serial PSA and, depending on the case, repeat imaging and targeted biopsy. That follow-up is not optional — it is part of the treatment, because treating one area means the rest of the prostate is still there and has to be watched. If disease appears later, focal treatment does not close the door on other options, though not all of them are left equally simple: radiation generally remains viable after a focal ablation, while radical surgery can become more technically demanding, because fibrosis in treated tissue changes the surgical planes. How much that weighs depends on the ablation modality and on your anatomy, and it is part of the conversation before you decide.
Two different questions get mixed together here, so it is worth separating them: whether you need the diagnostic pathway, and whether you are a candidate for focal treatment. Nobody is a candidate for ablation before a biopsy confirms cancer.
When it does not apply: high-risk, extensive or multifocal disease generally requires treating the whole gland or another approach. If that is your situation we say so plainly and coordinate the treatment that fits.
Dr. Gheiler is a co-author of these peer-reviewed publications on fusion biopsy and focal ablation:
This page is patient education and does not provide a diagnosis or an individual treatment recommendation. Focal therapy is not appropriate for every patient and results vary by case. Discuss your situation with your urologist.
It is an image-guided mapping biopsy. An MRI of the prostate is taken first, then the computer overlays that map onto live ultrasound so cores can be aimed at the suspicious spot — and systematic cores are also taken across the rest of the gland in the same sitting, because targeting alone can miss cancer the MRI did not show. It is taken through the perineum — the skin between the scrotum and the anus — under local anesthesia in the office, rather than through the rectum.
Instead of removing or irradiating the whole prostate, focal therapy applies energy only to the area where cancer was confirmed, with the intent of sparing the surrounding healthy tissue. Not everyone is a candidate: it depends on the grade, location and extent of the tumor.
Usually not. Early prostate cancer is typically silent, which is why it is found through PSA testing and examination rather than by how it feels. Urinary symptoms — weak stream, getting up at night, urgency — almost always come from an enlarged prostate (BPH), a different and benign condition. Waiting for symptoms is not a way to catch it early.
It is generally considered for men with localized low- or intermediate-risk prostate cancer whose lesion is clearly identified on MRI, confirmed on targeted cores, and whose systematic mapping cores show the rest of the gland clear. Targeted cores alone do not establish candidacy — they confirm the lesion, not the absence of disease elsewhere. High-risk, extensive or multifocal disease usually needs treatment of the whole gland or another approach. Dr. Gheiler reviews your imaging and pathology and tells you plainly which options apply.
These are two different questions. MRI and prostate biopsy, when medically indicated, are established studies. Focal treatment is different: some plans still classify it as investigational, coverage varies considerably, prior authorization is often required, and in some cases it is not covered. We will not tell you it is covered until we have verified it in writing with your plan — that happens before anything is scheduled, along with what your own cost would be. Ask us to verify your plan.
Request a consultation to review your studies and understand your options. English · Spanish. También en español: urofeliz.com.
Private and confidential from your first call: these are problems our office treats every day, with discretion and respect.
Call (305) 822-7227Happy Urology — Edward Gheiler, MD, FACS. 2140 W. 68th St. #200, Hialeah, FL 33016. (305) 822-7227